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Michael SnyderAbstract
Michael Snyder shares his thoughts on participatory
medicine and how omics profiling could fit into this
new model of healthcare where patients are at the
center of medicine.it’s in a range that you can now do this as a researchIntroduction
Michael Snyder (Figure 1) is the Chair of the Genetics
Department at Stanford University, California, USA, and
the Director of the Stanford Center for Genomics and
Personalized Medicine. Last year, his team published a
landmark article in Cell that presented Snyder’s own in-
tegrative personal omics profile (iPOP) [1]. His experi-
ence as a participant in genomic medicine and as a
researcher put him in a unique position to discuss par-
ticipatory medicine.
Last year you published a study about personal omics
profiling. Could you briefly describe what this is?
Personal omics profiling involves trying to bring to-
gether as many measurements as possible with the goal
of trying to understand a healthy and disease state in in-
credible detail. It involves sequencing someone’s gen-
ome, trying to get a complete picture of their molecular
profile, by determining their DNA methylome, transcrip-
tome, proteome, metabolome, auto-antibodyome, and
their microbiome in many different locations in the
body.
The ultimate goal is to have a very detailed assessment
of a person’s physiological state so that we can catch that
state when it goes aberrant; that is, when someone has a
predisposition for a disease or is on the verge of devel-
oping it.
Have there been any recent advances in this field?
As for new advances, there’s been a huge number. For
example, the ability to sequence genomes at an afford-
able cost, and the ability to measure completeCorrespondence: mpsnyder@stanford.edu
Stanford University, Department of Genetics, 300 Pasteur Drive, M-344
Stanford, CA 94305-5120, USA
© 2014 BioMed Central Ltd.transcriptomes using RNA sequencing. Proteomics has
had huge advances, as has metabolomics, thanks to ad-
vances in mass spectrometry. One can get a much more
complete and accurate picture of all these different
‘omes’ than we could even a few years ago. Also the
price has dropped quite a bit. It’s not super cheap, but
project. The whole thing has only become possible in
the past few years.Has your own attitude towards omics profiling changed
since the study was published?
I would say the answer is no. I’ve always been enthusias-
tic about trying to launch this project. It really only be-
came possible because of the drop in cost of the various
technologies and the ability to collect all the expertise in
one location. The first version of omics profiling in-
volved following about 40,000 molecules in my blood;
the latest follows billions of individual measurements.
This project is still evolving, but our ability to see things
at this level has never been possible before, although I
always envisioned it would be some day.What advice would you offer to people who are
interested in having their own profile studied?
At the moment it really is a research project. It’s not
routinely performed in the clinic because it involves tak-
ing lots of measurements, a complex analysis, and time
to understand the data. My own view is that in the long
run there will be some clinical form of this that involves
hundreds or thousands of measurements. Right now,
when you go to the doctor’s office, you get about 15
things measured in a routine blood test. So, what we’re
trying to do is add tens of thousands, if not millions or
billions of measurements. When it is applied in the
clinic, it is probable that a smaller number of very useful
markers would be used. It is just that we don’t know
what those markers are yet.
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in the clinic in future?
Not in the form we are doing it. At the moment we have a
very incomplete picture of what’s going on, whereas if we
were able to make thousands of measurements we would
have a much better feeling. We just don’t know, for the
clinical tests, which thousand measurements are going to
be most useful. We’ll need certain measurements for dia-
betes, others for cancer, and specific tests will probably re-
veal themselves useful for different diseases.
I would like to see this ultimately used as a home test
where an individual would prick their finger and make
literally thousands of measurements to assess their
health at high frequency, maybe once a month. We
really need more frequent and comprehensive tests to
follow someone’s health, rather than the current practice
of having individuals go to the doctor every two to three
years to get a standard medical test, which to my mind
is just woefully inadequate.
As we move toward healthcare that incorporates omics
profiling, what do you think will be the main challenges?
By the time it becomes a clinical test, the patient will sim-
ply be the recipient of it. For the moment, the biggest
challenge is cost and who pays. Right now, because it’s aresearch project, nobody is going to reimburse or cover it.
Ultimately, when it becomes clear that making more de-
tailed measurements saves money by actually preventing
disease, then I think this will be better received, especially
if we can set up low-cost tests. I think some degree of
omics profiling could occur for a few hundred dollars in
the future. I do think there will be some routine version
that will be sufficiently cheap that people would just pay
for it out of their own pockets, much like many pay for a
prescription for a statin.
How do you think the relationship between patients,
researchers, clinicians, and the general public might need
to change?
This relationship will change quite a bit, and it is chan-
ging already. People don’t realize that doctors really have
about 15 minutes to look at your profile, and make rec-
ommendations about the next steps for your health. I
don’t see that (the time) changing a whole lot; physicians
really don’t have the time. I think you’re going to see the
burden shift to the patient because nobody else has the
time to spend on your health like you do.
I think doctors are going to have to work with genomi-
cists, who will be interpreting DNA. They’ll have to work
with specialists who make recommendations about
whether you should be seeing a cardiologist or a nutrition-
ist for your metabolic conditions, based on your DNA or
omics profile. The patient really has to become more in-
volved, and the role of the physician will be to help coord-
inate that process by making sure that patients are seeing
the right people, and getting the right advice.
How will the relationship between researchers and the
general public change?
I think we, as researchers, need to educate the public
better. The public are very eager to learn. Everyone
knows something about their DNA or genes. I think we
have to learn not to be scared of using information to
help ourselves; a lot of people are scared about genetic
information and what it might mean. We should be try-
ing to understand genomic information to manage
healthcare better.
We might have to be careful in terms of the informa-
tion that is relayed back. But I really do think that it is
up to the individual to decide. Individuals are the gate-
way to their own genomic information; they should have
access to the genomic information that they feel com-
fortable with handling. Obviously, they do have to re-
ceive proper genetic counseling.
As a researcher and a research participant what are your
thoughts on participatory medicine?
Oh absolutely this is a good thing. We are all subjects in
an ongoing research trial. What is going to happen is
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medicine. As we collect information on individuals,
whether it’s clinical or research data, this will be shared
in a common database. As that database grows large
enough to have information about millions of people, we
should be able to make data-driven, rather than intuitive,
health decisions.
To explore this concept further, imagine a world
where there are a million genomes and electronic health
records. There’s no question we will soon be in a world
where we will be able to make links between treatments
and genetic information. I would like to see a million
longitudinal omic profiles like the one done on me
where we’re looking at a wide range of measurements.
Then, we would have a huge number of biomarkers to
better assess individuals' health states.
We would be so much more informed compared with
now. I would argue that we’re in the Stone Age com-
pared with where we’re going to be 20 years from now.
What significant advantages and challenges do you think
remain for the implementation of a participatory model
of healthcare?
I'd say the biggest challenge is a lack of research funding
for pilot studies, such as the one that we have launched
[1]. We are also going to need a good reimbursement
model, by which patients are reimbursed for getting
their exomes and their genomes sequenced. People
should get a discount on their healthcare if they get their
genome sequenced because, I think, they would be bet-
ter placed to get diseases identified and diagnosed earl-
ier. In principle, that is what should happen because
people who get their exome or genome sequenced will
be able to make health and lifestyle adjustments accord-
ingly based on their disease risks.
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